Biopharma company Atai Life Sciences' (NASDAQ:ATAI) fourth quarter and full year 2022 consolidated financial results show:
-
Cash, cash equivalents, and short-term investments totaling $273.1 million as of Dec. 31, 2022, lower than the $362.3 million in Dec. 31, 2021. The company expects its term loan facility with Hercules Capital Inc. to sustain operations into the first half of 2026.
-
R&D expenses totaled $21.9 million and $74.3 million for the three and twelve months ended Dec. 31, 2022, respectively, as compared to $13 million and $48.0 million for the same periods in 2021.
-
G&A expenses were $15.7 million and $70.4 million for the three and twelve months ended Dec. 31, 2022, respectively, as compared to $25.9 million and $92.7 million in the same periods in 2021.
-
Net loss attributable to shareholders was $45 million and $152.4 million for the three and twelve months ended Dec. 31, 2022, respectively, as compared to $88.9 million and $167.8 million for the comparable periods in 2021.
Clinical Psychedelics Pipeline Update
-
Synthetic psilocybin (COMP360) therapy for Treatment-Resistant Depression (TRD): program developer COMPASS Pathways (NASDAQ:CMPS) will accelerate the Pivotal Trial 1 part of the Phase 3 study, expecting topline data in summer 2024.
See Also:
-
Oral transmucosal DMT film VLS-01 for TRD: First subject was dosed in a Phase 1 study on 4Q 2022, with initial study results expected in H1 2023. The two-part trial assesses safety, tolerability and relative bioavailability of oral transmucosal film (OTF) versus intravenous (IV) formulations of VLS-01.
-
Ibogaine DMX-1002 for Opioid Use Disorder (OUD): First subject was dosed in a Phase 1/2 study on 3Q 2022, with initial results expected in H1 2023.
MDMA derivative EMP-01 for PTSD: A Phase 1 study began in Q3 2022, with initial results expected in H2 2023.
Photo: Benzinga edit with photo by chrissmith12 and Bru-nO on Pixabay.
